



UNIVERSITÀ POLITECNICA DELLE MARCHE

FACOLTÀ DI INGEGNERIA

Master's Degree in Biomedical Engineering

**Cross-Linking Strategies for Modulating Collagen Resorption
in Guided Bone Regeneration Applications**

Advisor:

Prof. Scalise Lorenzo

Candidate:

Irene Nardella

Co-advisor:

Dott. Fattori Paolo

Academic Year 2025/2026

TABLE OF CONTENTS

1	INTRODUCTION.....	1
1.1	Overview of Regenerative Medicine in Musculoskeletal Tissues.....	1
1.2	Cell Therapy	2
1.2.1	Types of Cells Used in Regenerative Therapy	2
1.3	Biomaterials in Regenerative Medicine.....	5
1.4	Tissue Engineering	7
1.5	In Situ Regeneration: Scaffolds	9
1.6	Collagen in Medical Devices for Tissue Regeneration	13
1.6.1	Structural and Chemical Composition of Collagen	15
1.6.2	Biological and Mechanical Properties	17
1.6.3	Applications of Collagen in GBR.....	19
1.7	Limitations of Collagen-Based Biomaterials	20
1.7.1	Challenges and Research on Extending Collagen Degradation and Resorption Time	20
1.8	Cross-Linking Techniques to Enhance Collagen Resorption Time	22
1.8.1	Types of Cross-Linking Methods	23
1.8.2	Comparative Analysis of Cross-Linking Techniques	25
1.9	Clinical and Ethical Considerations	26

2	<i>MATERIALS AND METHODS</i>	28
2.1	Materials and Sample Preparation	28
2.2	Digestive Enzyme Analysis for Resorption Testing.....	31
2.3	Analytical Techniques.....	34
3	<i>RESULTS</i>	36
3.1	Optimization of the Enzymatic Digestion Assay	36
3.2	Evaluation of EDC-Mediated Cross-Linking on Enzymatic Resistance .	39
4	<i>DISCUSSION</i>	41
4.1	Interpretation of Results	41
4.2	Effectiveness of Cross-Linking Methods	42
4.3	Future Directions for Collagen-Based GBR Biomaterials	43
5	<i>CONCLUSIONS</i>	45
6	<i>BIBLIOGRAPHY</i>	47

1 INTRODUCTION

1.1 Overview of Regenerative Medicine in Musculoskeletal Tissues

Bone is a dynamic, highly vascularized connective tissue that constantly remodels throughout life through the coordinated activity of osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). This continuous turnover allows the skeleton to maintain its mechanical strength, repair micro-damages, and adapt to mechanical stresses. Beyond its structural role in locomotion and protection of internal organs, bone also acts as a reservoir for minerals like calcium and phosphate, which are essential for various physiological processes [1].

The demographic shift toward an aging global population has amplified the burden of chronic diseases, musculoskeletal disorders, and degenerative conditions. While advances in acute care have significantly increased life expectancy, they have not addressed the underlying deterioration of tissues associated with aging or disease. In this scenario, regenerative medicine emerges as a transformative field, aiming not just to treat symptoms, but to repair, replace, or regenerate human cells, tissues, and organs to restore normal function [2].

Regenerative Medicine (RM) is inherently interdisciplinary, merging biology, materials science, engineering, and clinical medicine. It involves a suite of therapeutic strategies, including cell therapy, tissue engineering, biomaterial design, gene therapy, and molecular biology. These strategies are not mutually exclusive; rather, they often work synergistically to enable functional tissue regeneration. RM's goal is to provide durable, often permanent solutions for conditions previously deemed irreversible, such as spinal cord injuries, heart failure, or large bone defects [3]. One distinguishing feature of RM is its ability to stimulate the body's intrinsic healing capabilities. This may involve the activation of endogenous stem cells, the reconstitution of extracellular matrices, or the recruitment of immune and vascular systems to promote functional repair. Compared to traditional organ transplantation, regenerative strategies reduce the risk of immunological

rejection and the need for lifelong immunosuppressive therapy, as they often employ autologous or well-integrated biological components [4].

1.2 Cell Therapy

Cell therapy refers to the therapeutic administration of live cells to a patient to repair or replace damaged tissues. These therapies leverage the unique properties of certain cells—particularly stem cells—to enhance tissue regeneration, modulate immune responses, and improve functional recovery in degenerative or traumatic conditions. The field encompasses a wide array of cell types and delivery strategies and is closely interlinked with advancements in scaffold technologies and gene editing.

1.2.1 Types of Cells Used in Regenerative Therapy

Stem cells

Stem cells are the cornerstone of many regenerative therapies due to their defining features: self-renewal and potency. These undifferentiated cells can both replicate indefinitely and differentiate into specialized cell types, depending on their origin and the environmental cues they receive. Their versatility has made them the subject of intense investigation in tissue engineering and regenerative medicine [5].

Stem cell therapy can be autologous (using the patient's own cells) or allogeneic (using donor-derived cells), with each approach having its own advantages. Autologous therapies avoid immune rejection, while allogeneic sources allow for off-the-shelf availability and consistency. These cells are categorized by their differentiation potential:

- **Totipotent** cells (e.g., zygote) can generate all cell types, including extraembryonic tissues.
- **Pluripotent** cells (e.g., ESCs, iPSCs) can differentiate into all three germ layers: ectoderm, mesoderm, and endoderm.
- **Multipotent** cells (e.g., MSCs) give rise to cells within a specific lineage, such as bone, cartilage, or fat.

- Unipotent cells can differentiate into only one cell type but retain self-renewal capacity.

Induced pluripotent stem cells (iPSCs), created by reprogramming adult somatic cells, provide a powerful alternative to embryonic stem cells (ESCs), offering similar differentiation capacity without the associated ethical concerns. Their application ranges from disease modeling and drug screening to personalized regenerative therapies, with ongoing research into improving their genomic stability and differentiation control.

Mesenchymal stem cells (MSCs), primarily sourced from bone marrow, adipose tissue, and umbilical cord, are widely used in preclinical and clinical studies. Their appeal lies not only in their multipotency but also in their immunomodulatory, anti-inflammatory, and trophic functions. MSCs secrete a variety of cytokines and growth factors that promote angiogenesis, anti-apoptotic signaling, and extracellular matrix remodeling, contributing to tissue repair even without direct differentiation.

Stem cells can also be grouped by their developmental origin:

- **Embryonic stem cells (ESCs):** Derived from the inner cell mass of blastocysts.
- **Fetal stem cells (FSCs):** Obtained from fetal tissues or extraembryonic structures.
- **Adult stem cells (ASCs):** Reside in various tissues and maintain homeostasis and repair capacity throughout life.

Despite their promise, stem cell therapies face several limitations, such as risk of tumorigenesis, low engraftment efficiency, and immune rejection, especially when not autologous [6]. Robust preclinical validation and long-term safety data remain essential for clinical translation.

Exosomes

Exosomes are nanoscale, lipid-enclosed vesicles secreted by most eukaryotic cells as part of their intercellular communication network. Derived from the endosomal compartment, they are formed within multivesicular bodies (MVBs) and released upon fusion with the plasma membrane. These vesicles transport a cargo of biologically active molecules—

including proteins, lipids, mRNAs, and microRNAs (miRNAs)—which can modulate gene expression and signaling pathways in target cells.

In regenerative medicine, exosomes have gained considerable attention due to their role as mediators of tissue repair. Unlike whole-cell therapies, they offer a cell-free alternative that retains the paracrine effects of the parent cells without the associated risks, such as tumorigenicity or immune rejection. This is particularly relevant when using mesenchymal stem cell-derived exosomes, which have demonstrated therapeutic potential in several tissue types.

These exosomes contribute to regeneration through various mechanisms:

- Delivering growth factors and miRNAs that stimulate cell proliferation and survival
- Enhancing angiogenesis via pro-angiogenic molecules
- Promoting neurogenesis and modulation of the inflammatory response
- Supporting extracellular matrix remodeling and tissue repair

Several preclinical studies have shown that exosomes derived from MSCs can promote healing in tissues such as nerve, cardiac, dermal, and bone, by mimicking the regenerative cues typically provided by transplanted cells. Their molecular cargo is now being characterized to identify the key components responsible for these effects, enabling the development of engineered exosomes with enhanced therapeutic profiles [7]. Additionally, exosomes are stable in biological fluids and can be stored and transported more easily than live cells, offering a promising platform for off-the-shelf regenerative therapies. However, challenges such as standardization of isolation protocols, dosage, and targeted delivery remain significant hurdles before their widespread clinical adoption.

1.3 Biomaterials in Regenerative Medicine

Biomaterials are fundamental components in regenerative medicine, functioning as scaffolds or structural supports that facilitate the repair and regeneration of damaged tissues. As defined by the American National Institute for Health (NIH), a biomaterial is any substance -excluding drugs- whether synthetic or natural, that can be used for any period to augment or replace tissues, organs, or bodily functions, with the goal of improving a patient's quality of life.

In regenerative contexts, biomaterials serve more than just structural roles; they actively interact with biological systems. By mimicking the properties of the natural extracellular matrix (ECM), biomaterials provide mechanical support and biochemical signals that influence cell adhesion, migration, proliferation, and differentiation. This dynamic interaction guides tissue regeneration in a controlled and often localized manner.

Biomaterials can be broadly divided into four major categories based on their origin and properties:

- **Non-degradable synthetic polymers:** These include materials such as poly(methyl methacrylate) (PMMA) and poly(ethylene terephthalate) (PET), known for their long-term mechanical stability. While they provide structural support, their permanence within the body may lead to chronic inflammation or fibrosis in some cases.
- **Biodegradable synthetic polymers:** Polymers such as poly(lactic acid) (PLA) and poly(glycolic acid) (PGA) are widely used due to their ability to degrade into non-toxic by-products. This degradation facilitates gradual tissue integration, allowing the material to be replaced by native tissue over time.
- **Ceramics and bioactive glasses:** These inorganic materials, including β -Tricalcium Phosphate (β -TCP) and silica-based bioactive glasses, are especially relevant for bone regeneration due to their osteoconductivity and compositional similarity to bone mineral. They support cell attachment and can promote mineralization.

- **Natural materials:** Derived from biological sources, materials like collagen, chitosan, and hyaluronic acid exhibit excellent biocompatibility. They inherently promote cellular activities, although their mechanical properties and degradation profiles often require enhancement for load-bearing applications [8].

A key advantage of natural biomaterials is their enzymatic degradability and resemblance to native tissue components, which fosters better biological integration. However, they may lack mechanical strength and consistency. Synthetic materials, in contrast, allow precise tuning of properties such as stiffness, degradation rate, and surface chemistry, offering design flexibility but sometimes at the expense of biocompatibility [9].

Innovative biomaterial designs aim to combine the best of both worlds through composite materials or hybrid systems, such as polymer-ceramic blends or collagen-based scaffolds reinforced with synthetic fibers. These combinations seek to optimize performance in terms of both biological activity and mechanical resilience.

Applications for these biomaterials span a wide range of regenerative fields. In bone regeneration, calcium phosphate ceramics and collagen-based matrices are widely employed [10]. For cartilage and nerve tissue engineering, biodegradable polymers and hydrogels provide structural support while promoting cellular growth [11] [12].

These biomaterials demonstrate considerable potential in supporting the regeneration of bone, cartilage, and nerve tissues, primarily due to their capacity to establish a conducive microenvironment that promotes cellular activity, facilitates communication between transplanted and host cells, and encourages proper tissue integration and repair. They not only serve as passive structural supports but also as active participants in tissue regeneration by modulating cellular responses, improving integration, and accelerating healing processes [13] [14].

Ultimately, the design and selection of a biomaterial depend on the specific requirements of the target tissue, such as mechanical load, biological environment, degradation timeline, and immune compatibility. The continuous development of smart biomaterials—capable of responding to environmental stimuli or delivering therapeutic

agents—represents a promising frontier in regenerative medicine, enabling more efficient and personalized treatments.

1.4 Tissue Engineering

Tissue engineering (TE) is an interdisciplinary field that integrates the principles of engineering and life sciences to develop biological substitutes capable of restoring, maintaining, or improving tissue function. Unlike traditional reconstructive approaches that rely on prosthetic devices or donor tissues, tissue engineering offers the opportunity to construct living, patient-specific tissues designed to match the physiological and anatomical needs of the recipient.




Figure 1.1 Schematic representation of the tissue engineering approach, illustrating the integration of patient-derived cells, biological factors, and biomaterial scaffolds to generate tissue-engineered grafts for regenerative medicine applications.

A central component of tissue engineering is the use of living cells, which serve as the active agents for tissue formation and integration. Virtually every tissue type in the human body has been investigated in this context, and most studies have focused on specific cell populations relevant to the tissue of interest. For clinical applications, cells are commonly obtained from the patient (autologous), a genetically similar donor (allogeneic), or unrelated donors.

However, sourcing sufficient and appropriate cells remains a major challenge. To overcome this limitation, considerable research has focused on the isolation and use of human stem cells—cells that can self-renew over multiple generations and differentiate into various specialized lineages. Embryonic stem cells have demonstrated the potential for broad differentiation capabilities.

A critical objective in this field is to gain precise control over the differentiation process, ensuring that stem or progenitor cells adopt and maintain the correct functional identity after implantation. Achieving this requires optimization of culture protocols, development of methods to eliminate contaminating cell types (e.g., fibroblasts), and scaling up production to obtain the large cell numbers needed for therapeutic use. An example are the so-called "universal donor" cells, cells engineered to evade immune detection by masking their surface histocompatibility proteins—molecules that would normally signal the immune system to reject foreign cells.

In parallel with advancements in cell sourcing, in vitro cultivation systems have evolved significantly. Traditional static cultures are being replaced or supplemented by dynamic bioreactor systems that provide mechanical stimulation, enhance mass transfer of nutrients and oxygen, and remove metabolic waste. These systems improve both the biochemical composition and mechanical performance of engineered tissues.

Ultimately, the clinical success of tissue engineering depends on addressing critical challenges such as immune compatibility, vascularization, and scalable production. Continued interdisciplinary collaboration is essential to translate promising laboratory findings into robust, clinically approved therapies. Tissue engineering is an interdisciplinary field that combines the principles of engineering and life sciences to develop biological substitutes capable of restoring, maintaining, or enhancing tissue function. It represents a transformative approach in regenerative medicine, as it moves beyond traditional solutions such as prosthetics or donor-derived grafts, offering instead the potential to construct living, patient-specific tissues [7].

1.5 In Situ Regeneration: Scaffolds

In tissue engineering (TE), scaffold-based strategies represent a cornerstone approach for promoting *in situ* tissue regeneration, leveraging the intrinsic healing potential of the body to repair or replace damaged tissues directly at the implantation site. Rather than relying solely on exogenous cell delivery, *in situ* regeneration focuses on creating a permissive microenvironment that supports endogenous cell recruitment, adhesion, proliferation, and differentiation. Within this framework, scaffolds play a pivotal role as temporary, three-dimensional (3D) support structures that guide tissue regeneration by mimicking key features of the native extracellular matrix (ECM).

Scaffolds are engineered biomaterial constructs designed to act as physical and biological templates for tissue formation. By providing a 3D architecture, scaffolds facilitate spatial organization of cells and enable the deposition of newly synthesized ECM components, which are essential for the development of functional tissue. In addition to offering structural support, scaffolds influence cellular behavior through surface chemistry, topography, and mechanical cues, thereby regulating cell–material interactions that are fundamental to regenerative processes.

The design of an ideal scaffold for tissue regeneration requires the careful integration of multiple criteria, each contributing to the overall biological performance and clinical applicability of the construct. One of the primary requirements is **biocompatibility**, which ensures that the scaffold can support cell attachment, proliferation, and differentiation without eliciting cytotoxic effects or adverse immune reactions. A biocompatible scaffold must interact harmoniously with the host tissue, enabling both *in vitro* cellular studies and successful *in vivo* implantation while minimizing inflammatory responses and fibrous encapsulation.

Another critical property is **osteoconductivity**, particularly relevant in bone tissue engineering and guided bone regeneration (GBR). An osteoconductive scaffold promotes the adhesion and migration of osteogenic cells and supports the deposition of mineralized matrix within its structure. This characteristic enables the scaffold to act as a conduit for

new bone growth, facilitating the natural regenerative cascade that leads to defect healing and structural restoration.

Biodegradability is equally essential, as the scaffold is intended to serve as a temporary support rather than a permanent implant. Ideally, scaffold degradation should occur in a controlled and predictable manner, synchronized with the rate of new tissue formation. This balance allows the gradual transfer of mechanical load from the scaffold to the newly regenerated tissue, preventing premature collapse or prolonged persistence of foreign material that could interfere with normal healing processes.

From a mechanical standpoint, scaffolds must possess adequate **mechanical properties** to maintain structural integrity throughout the regenerative phase. This requirement is particularly critical in load-bearing applications, where insufficient mechanical strength may lead to scaffold deformation or failure. At the same time, excessive stiffness can hinder tissue integration, highlighting the need for a carefully tuned mechanical profile that matches the target tissue.

The **porous architecture** of a scaffold is a defining feature that directly impacts its biological performance. High porosity levels, typically exceeding 90%, combined with an interconnected pore network, are essential for effective tissue regeneration. Pore diameters in the range of 300–500 μm are generally considered optimal for bone tissue engineering, as they facilitate deep cell infiltration, promote vascular ingrowth, and enhance the transport of nutrients, oxygen, and metabolic waste. Interconnectivity between pores is particularly important to ensure continuous pathways for cell migration and neovascularization, which are critical for sustaining tissue viability within the scaffold interior.

In addition to biological and mechanical considerations, **fabrication flexibility** represents a practical design criterion. Scaffold materials and processing techniques must allow the production of constructs with customizable geometries, enabling adaptation to patient-specific anatomical defects. This flexibility is especially relevant in clinical scenarios involving irregular or complex bone defects, where precise scaffold shaping can significantly improve surgical outcomes.

Finally, **commercial viability** is a non-negligible factor for the successful translation of scaffold-based technologies into routine clinical practice. Scaffolds must be manufacturable at a reasonable cost, using scalable and reproducible processes that comply with regulatory standards. Achieving a balance between advanced material performance and economic feasibility is crucial for widespread adoption and long-term clinical impact [15].




Figure 1.2 Schematic overview of the main characteristics required for an ideal biomaterial scaffold in tissue engineering, including biocompatibility, controlled degradation, three-dimensional architecture, mechanical properties, surface characteristics, fabrication techniques, and scaffold geometry.

In addition, scaffolds can be classified according to their material composition, including metals, ceramics, natural polymers, synthetic polymers, and composite systems. The selection of a specific material depends on the intended tissue application, as each class exhibits distinct biological, mechanical, and degradation characteristics. In parallel, scaffolds may also be categorized based on the presence or absence of living cells prior to implantation. **Acellular** scaffolds rely on bioactive cues, such as incorporated growth factors or surface functionalization, to stimulate endogenous cell recruitment and tissue regeneration following implantation. By contrast, **cellular** scaffolds are pre-seeded with viable cells, providing an immediate cellular component that can enhance tissue formation and address challenges such as poor cell survival, low retention, and limited

engraftment commonly observed in cell-only therapeutic approaches. Together, these strategies underscore the versatility of scaffold-based tissue engineering and its significant potential for improving regenerative outcomes in both soft and hard tissues [7].

The fabrication of scaffolds for tissue engineering applications relies on a variety of conventional manufacturing techniques, each offering specific benefits while presenting inherent limitations:

- **Fiber Bonding (Unwoven Mesh):** This method yields scaffolds with a high surface-to-volume ratio and porosity of approximately 81%. While this configuration supports cell attachment, the resulting mechanical properties are relatively poor, restricting its use to select polymer systems. Typical pore sizes achieved through this method are around 500 μm .
- **Solvent Casting/Particulate Leaching:** This technique enables controlled tuning of porosity, pore size, and polymer crystallinity, achieving porosity levels close to 87%. However, the presence of residual solvents or porogens can negatively affect scaffold biocompatibility and mechanical performance. Pore sizes generated through this approach are generally around 100 μm .
- **Gas Foaming/Particulate Leaching:** Porosity values can reach up to 93% without the use of harsh organic solvents. Despite this advantage, this method often results in limited pore interconnectivity and suboptimal mechanical strength, with pore sizes typically around 100 μm .
- **Phase Separation/Emulsification:** Offering up to 95% porosity, this method avoids loss of biological activity within the scaffold. However, scaffold morphology is challenging to control precisely, and pore sizes range between 13–35 μm .
- **Freeze-Drying:** Also known as lyophilization, it is widely employed due to its ability to generate highly porous structures without exposing the material to elevated temperatures or additional leaching steps. This method can produce pore sizes up to 500 μm and porosity levels of approximately 81%, although it is associated with long processing times and limited control over pore uniformity.

- **Melt Molding:** It offers independent control over pore size and overall porosity, achieving values of up to 90%. The requirement for high processing temperatures limits its applicability to thermally stable polymers, with typical pore sizes ranging between 200 and 300 μm [8].

Collectively, these fabrication techniques illustrate the inherent trade-off between porosity, mechanical stability, and structural control in scaffold design. The selection of an appropriate manufacturing method is therefore closely linked to the target tissue and clinical application, with ongoing research efforts focused on optimizing scaffold architecture and performance to meet the increasingly complex demands of regenerative therapies.

1.6 Collagen in Medical Devices for Tissue Regeneration

Collagen is the most abundant protein in mammals, accounting for more than one-third of the total protein content of the human body. Its widespread presence reflects its fundamental role in tissue morphogenesis, structural organization, and cellular metabolism. Within the extracellular matrix (ECM), collagen provides both mechanical stability and biochemical signals that are essential for maintaining tissue integrity and regulating cell behavior. These characteristics make collagen a key structural and functional component in virtually all connective tissues and a highly attractive biomaterial for medical device applications in tissue regeneration [16].

The ECM is a complex, dynamic, and highly organized network composed of structural proteins, glycoproteins, proteoglycans, and signaling molecules. Its primary function is to confer tissue-specific mechanical properties while simultaneously modulating cellular functions such as adhesion, migration, proliferation, and differentiation. Among the various ECM constituents, collagens represent the predominant protein family, forming fibrillar and non-fibrillar architectures that create a supportive extracellular framework. This framework not only maintains tissue architecture but also acts as a reservoir for growth factors and bioactive molecules, thereby contributing to tissue homeostasis and repair.

Historically, collagens were regarded as a relatively uniform class of proteins, primarily defined by their characteristic triple-helical molecular structure. Advances in molecular biology over the past decade have significantly expanded this view, leading to the identification of at least 28 distinct collagen types. Each collagen type exhibits unique structural features, tissue distributions, and biological functions, reflecting a high degree of specialization within the collagen superfamily [17]. This diversity allows different collagen types to fulfill specific mechanical and biological roles across a wide range of tissues.

Despite their heterogeneity, most collagen molecules share a common structural motif consisting of three polypeptide chains arranged in a right-handed triple helix. This structure is stabilized by repeating glycine-containing sequences, which enable tight molecular packing.

Among the various collagen types, type I collagen is the most abundant and extensively studied. It constitutes more than 90% of the organic matrix of bone and is the principal collagen found in tendons, ligaments, skin, cornea, and most interstitial connective tissues. Conversely, it is largely absent in specialized tissues such as hyaline cartilage, the brain, and the vitreous body. The prevalence of type I collagen in load-bearing tissues underscores its critical role in providing tensile strength and mechanical resilience, properties that are essential for maintaining structural integrity under physiological stress.

Due to its favorable structural and biomechanical characteristics, type I collagen is widely utilized in biomedical applications, particularly in bone tissue engineering and regenerative medicine. Collagen-based medical devices, including membranes, sponges, and scaffolds, are commonly employed to support tissue regeneration by providing a biomimetic environment that closely resembles the native ECM. The intrinsic bioactivity of collagen facilitates cell adhesion and migration while promoting ECM deposition and tissue remodeling.

Beyond its mechanical function, collagen actively participates in a variety of biological processes that are central to tissue regeneration. It plays a role in cell signaling through interactions with cell surface receptors, influences immune responses by modulating

inflammatory pathways, and contributes to ECM remodeling during wound healing and regeneration. The ability of collagen to undergo enzymatic degradation, self-assemble into fibrillar structures, and interact synergistically with other ECM components highlights its versatility as a biomaterial [17].

Collectively, these properties position collagen as a cornerstone material in the design of medical devices for tissue regeneration. Its structural adaptability, biological compatibility, and functional integration within the ECM make it particularly suitable for applications where controlled degradation, tissue integration, and biological performance are critical, such as in guided bone regeneration strategies.

1.6.1 Structural and Chemical Composition of Collagen

Collagen exhibits a highly organized and hierarchical architecture that spans multiple structural levels, each contributing to its unique mechanical strength and biological functionality. This hierarchical organization can be described through four main levels: the primary structure, corresponding to the amino acid sequence; the secondary structure, characterized by individual α -helices; the tertiary structure, represented by the collagen triple helix; and the quaternary structure, consisting of higher-order assemblies such as collagen fibrils and fibers [17].




Figure 1.3 Hierarchical structure of collagen, showing the organization of collagen molecules into microfibrils and fibrils, as well as the natural intra- and intermolecular cross-links that contribute to the mechanical stability and enzymatic resistance of collagen [27].

The integration of these structural levels underlies the remarkable stability, flexibility, and load-bearing capacity of collagen-based tissues [17].

Primary Structure: Amino Acid Triplet

At the primary structural level, collagen is defined by a distinctive repetitive amino acid motif, commonly referred to as the Gly–X–Y triplet. In this sequence, glycine (Gly) occupies every third position, a feature that is essential for the tight packing of the three polypeptide chains within the triple helix. The small size of glycine allows it to fit into the restricted central core of the helical structure. The X and Y positions are most frequently occupied by proline and hydroxyproline, respectively, amino acids that play a crucial role in stabilizing the collagen molecule. Hydroxyproline, a post-translationally modified derivative of proline, is a hallmark of collagen and contributes significantly to its thermal and conformational stability, accounting for more than half of the total amino acid content of the molecule.

Secondary Structure: α -Helix

The secondary structure of collagen consists of individual α -chains that adopt a left-handed helical conformation. These α -chains are composed of repeated (Gly–X–Y)_n sequences and serve as the fundamental building blocks of the collagen molecule. At the terminal regions of the α -chains, non-helical domains known as telopeptides are present. These regions do not participate directly in the triple helix but play a critical regulatory role in collagen assembly by influencing fibril diameter and facilitating intermolecular interactions. Covalent cross-links formed between telopeptides of adjacent molecules contribute to the structural integrity and mechanical stability of the collagen network within the extracellular matrix.

Tertiary Structure: Triple Helix

The tertiary structure of collagen is defined by the formation of the characteristic triple helix, which represents the molecular hallmark of this protein family. In type I collagen, the triple helix is composed of two identical $\alpha 1(I)$ chains and one $\alpha 2(I)$ chain, assembled into a right-handed superhelix. This helical domain measures approximately 300 nm in

length and 1.5 nm in diameter, providing an extended and rigid molecular structure. The stability of the triple helix is ensured by a combination of hydrogen bonding between glycine residues and neighboring amino acids, as well as additional interstrand interactions. The C-terminal domain plays a pivotal role in initiating chain association and guiding the correct alignment of the α -chains, thereby stabilizing the heterotrimeric configuration.

Quaternary Structure: Collagen Fibrils

At the quaternary structural level, individual collagen molecules spontaneously self-assemble into fibrils through a highly ordered quarter-staggered arrangement. In this configuration, five triple-helical molecules are longitudinally aligned with a characteristic D-periodic banding pattern of approximately 67 nm, a defining feature observable by electron microscopy. The mechanical strength and durability of collagen fibrils are largely dependent on intermolecular cross-linking, which enhances resistance to mechanical stress and enzymatic degradation. These cross-links are classified into enzymatic (mediated by lysyl oxidase) and non-enzymatic (advanced glycation end products, AGE) cross-links. Enzymatic cross-linking involves hydroxyl lysyl-pyridinoline (HP) and lysyl-pyridinoline (LP), which are formed through aldehyde-mediated reactions between lysine and hydroxylysine residues. Collagen fibrils are embedded within a supramolecular matrix composed of proteoglycans, glycosaminoglycans (GAGs), and glycoproteins. These macromolecules interact with collagen and help regulate tissue hydration and ECM organization, ultimately influencing the biomechanical properties of connective tissues [18].

1.6.2 Biological and Mechanical Properties

Collagen exhibits a wide range of biological and mechanical properties that make it one of the most widely used biomaterials in tissue engineering and regenerative medicine. These properties arise from its unique molecular structure, hierarchical organization, and dynamic interactions with cells and extracellular matrix components. Key characteristics of collagen include its solubility, high tensile strength, controlled biodegradability, low immunogenicity, and its ability to actively mediate cellular interactions.

From a biological perspective, collagen serves as a natural substrate for cell adhesion, proliferation, migration, and differentiation. Its molecular structure contains specific binding motifs that are recognized by cell surface receptors, enabling direct cell–matrix interactions that regulate essential cellular functions. Within the extracellular matrix, collagen interacts synergistically with other macromolecules such as glycosaminoglycans, proteoglycans, and fibronectin, forming an integrated network that provides both mechanical support and biochemical signaling cues. This cooperative interaction creates a favorable microenvironment for tissue development and regeneration. Collagen also plays an active role in wound healing and tissue repair through its bioactive properties. During tissue injury, collagen fragments generated through enzymatic cleavage can act as signaling molecules, promoting cell recruitment and guiding fibrillar structure reorganization at the repair site. The ability of collagen to self-assemble into fibrils further supports the restoration of tissue architecture during the healing process.

A defining feature of collagen as a biomaterial is its controlled biodegradability. Under physiological conditions, collagen degradation is primarily mediated by specific enzymes known as collagenases, which cleave the triple-helical structure in a regulated manner. This enzymatic degradation allows collagen-based constructs to be gradually resorbed and replaced by newly formed tissue, ensuring that no permanent foreign material remains following implantation.

From a mechanical standpoint, collagen is characterized by high tensile strength combined with relatively low extensibility, properties that are essential for maintaining the structural integrity of connective tissues. These mechanical characteristics depend on multiple factors, including fibril diameter, molecular alignment, and the density of intra- and intermolecular cross-links. Interactions with glycoproteins and proteoglycans within the extracellular matrix further modulate the load-bearing behavior of collagen-rich tissues.

Covalent cross-links within and between collagen molecules are a key determinant of mechanical stability. These cross-links enhance resistance to tensile and compressive forces and contribute to the long-term durability of collagen-based structures.

Another advantage of collagen is its low immunogenicity, particularly when used in a purified and non-denatured form.

Collectively, these biological and mechanical properties underpin the extensive use of collagen in medical devices and regenerative therapies. Its combination of bioactivity, mechanical competence, biodegradability, and immunological safety makes collagen a highly versatile biomaterial, particularly well-suited for applications in tissue engineering and guided bone regeneration [19].

1.6.3 Applications of Collagen in GBR

Guided Bone Regeneration (GBR) is a widely used strategy in dental and orthopedic applications to promote bone healing by providing a physical barrier that prevents soft tissue ingrowth while facilitating osteogenesis. Collagen-based biomaterials have emerged as essential components of GBR due to their biocompatibility, bioresorbability, and capacity to support cellular functions critical for bone regeneration.

Collagen scaffolds mimic the native extracellular matrix (ECM) of bone, providing structural and biochemical cues that guide osteoblast proliferation, differentiation, and matrix deposition. A major advantage of collagen-based GBR membranes is their ability to enhance regenerative processes without the need for exogenous stem cells or growth factors. Recent studies have demonstrated that mineralized collagen (MC) scaffolds, which incorporate both collagen and hydroxyapatite-like minerals, can improve bone healing outcomes by promoting osteogenic differentiation, modulating immune responses, and enhancing vascularization.

The mechanical properties and degradation rates of collagen-based GBR membranes can be tuned through cross-linking strategies or integration with other biomaterials, such as glycosaminoglycans, to improve their stability and osteogenic potential.

Another key feature of collagen-based GBR materials is their role in vascularization, which is crucial for the long-term success of bone regeneration. Studies have highlighted that anisotropic collagen scaffolds, designed with aligned pore structures, enhance mineral deposition and stimulate the secretion of pro-angiogenic factors, improving bone

integration and healing outcomes. Furthermore, MC scaffolds incorporating allogeneic tissues, such as placental-derived membranes, have shown increased immunomodulatory and antibacterial properties, further enhancing GBR efficacy.

Taken together, collagen-based GBR membranes, particularly those incorporating mineralization strategies, represent a promising avenue for enhancing bone repair by providing a bioactive, osteoinductive, and immunomodulatory environment. Future research should focus on optimizing mechanical properties, degradation kinetics, and patient-specific adaptations to further improve clinical outcomes [20].

1.7 Limitations of Collagen-Based Biomaterials

Collagen-based membranes are widely utilized biomaterials for guided bone and tissue regeneration. Nevertheless, despite these advantages, their performance as barrier devices may be limited by intrinsic material characteristics that can compromise regenerative outcomes. One of the most significant challenges associated with collagen-based membranes is their tendency toward relatively rapid degradation under physiological conditions, which may result in a premature loss of barrier function before complete bone regeneration has occurred. Variability in degradation behavior can arise from multiple factors, including the biological source of collagen, differences in extraction and purification processes, and the inherent structural characteristics of the collagen matrix. Additionally, functional modifications introduced to improve mechanical strength, handling properties, or biological performance may further influence the resorption profile of the membrane. These variations can lead to inconsistent clinical outcomes, highlighting the need for a deeper understanding and precise control of collagen degradation mechanisms.

1.7.1 Challenges and Research on Extending Collagen Degradation and Resorption Time

An ideal biomaterial barrier should maintain its structural integrity, spatial positioning, and functional stability throughout the entire healing period, until newly formed bone is sufficiently matured and integrated with the surrounding tissues. A key requirement in

this context is the ability of the membrane to maintain volumetric stability over time, which is crucial for successful outcomes in guided bone regeneration (GBR) and guided tissue regeneration (GTR) procedures, ensuring the creation and preservation of a protected regenerative space. Failure to maintain this stability can directly compromise the regenerative cascade, leading to not ideal clinical outcomes. Native collagen membranes, however, present inherent limitations related to their relatively short duration of barrier functionality. Their degradation rate under physiological conditions is often unpredictable and strongly influenced by the local biological environment, including the presence and activity of tissue-specific enzymes such as collagenases [21]. As a result, collagen membranes may undergo rapid enzymatic resorption that precedes adequate tissue formation. This issue is particularly critical in the treatment of large or complex defects, which require extended healing times and prolonged barrier function. In such cases, premature membrane degradation can allow soft tissue invasion into the defect site, ultimately impairing bone regeneration and reducing the overall success of GBR and GTR procedures.

To overcome these challenges, extensive research efforts have been directed toward strategies aimed at prolonging the structural stability and functional lifespan of collagen membranes. One approach involves structural modifications of the membrane, including variations in collagen source, processing techniques, and membrane thickness. These parameters can significantly influence fibril organization, density, and resistance to enzymatic degradation, thereby extending the effective resorption time of the material [22]. A critical factor governing collagen stability is the density of intermolecular cross-links within the fibrillar network. Increased cross-linking restricts molecular mobility and reduces the accessibility of enzymatic cleavage sites, effectively hindering hydrolytic and enzymatic degradation. Consequently, cross-linking techniques have emerged as a powerful strategy to slow collagen resorption and prolong membrane functionality. However, excessive or inappropriate cross-linking may negatively impact biological performance by altering cellular responses, impairing tissue integration, or triggering inflammatory reactions. These potential trade-offs highlight the need for carefully optimized cross-linking approaches that balance mechanical stability with biocompatibility. In addition to cross-link density, membrane properties such as porosity,

thickness, and overall mass play a decisive role in determining degradation behavior. These structural parameters directly influence how long the membrane can maintain its barrier role in vivo, thereby affecting clinical outcomes in regenerative procedures [23].

Given the structural and functional variability observed among commercially available collagen membranes, there is growing interest in the development of advanced membrane designs that extend beyond a purely passive barrier function. Recent research has focused on functionalized collagen membranes capable of actively participating in the healing process through the incorporation of bioactive molecules, drug-delivery systems, or osteogenic cues. By modulating the biochemical environment at the regeneration site, these next-generation membranes aim not only to provide mechanical separation but also to enhance osteoconductivity, support angiogenesis, and regulate inflammatory responses. Such multifunctional approaches represent a promising direction for improving the predictability and effectiveness of collagen-based regenerative therapies [24].

1.8 Cross-Linking Techniques to Enhance Collagen Resorption Time

Collagen exhibits a hierarchical organization in which tropocollagen molecules assemble into fibrils, fibers, and progressively higher-order structures, whose mechanical integrity is largely governed by covalent intermolecular cross-links. These cross-links play a central role in stabilizing the collagen network and enabling effective force transmission by restricting intermolecular sliding.

While native collagen is widely appreciated for its favorable biological properties, including biocompatibility and low immunogenicity, it is characterized by a limited and poorly controllable resorption time in vivo. This intrinsic limitation can reduce its effectiveness in applications requiring prolonged mechanical support. The mechanical stability and degradation behavior of collagen fibrils are closely linked to the density and nature of their covalent intermolecular cross-links, which enhance tensile resistance and slow degradation by limiting molecular mobility [25]. Increased cross-linking has been shown to improve mechanical durability and resistance to enzymatic breakdown; however, excessive or uncontrolled cross-link formation may lead to overly stiff and

brittle matrices, adversely affecting tissue function and cell–matrix interactions [26]. These considerations highlight the importance of carefully regulating cross-link density when designing collagen-based biomaterials [27].

To address the challenge of rapid or unpredictable collagen resorption, cross-linking techniques have therefore been extensively investigated as a strategy to modulate degradation kinetics and prolong functional performance. By introducing additional intermolecular bonds, cross-linking enhances structural stability, increases resistance to proteolytic enzymes, and improves mechanical properties while largely preserving the native characteristics of the collagen matrix. In addition, cross-linking has been reported to reduce collagen antigenicity, further supporting its clinical applicability [28].

Broadly, cross-linking approaches can be categorized into chemical and physical methods, each associated with distinct stabilization mechanisms and biological implications. Although these strategies differ in their degree of effectiveness and potential impact on biocompatibility, the careful selection and optimization of cross-linking methods is critical, as it directly influences collagen resorption time, mechanical behavior, and biological response, ultimately determining the clinical performance of collagen-based regenerative devices.

1.8.1 Types of Cross-Linking Methods

The process of cross-linking can be achieved through chemical or physical methods. Each approach modifies the molecular structure of collagen to improve its stability and mechanical properties while preserving, as much as possible, its natural bioactivity.

Chemical Cross-Linking

Chemical cross-linking methods involve the use of chemical agents that promote the formation of covalent bonds between collagen molecules, with the primary aim of improving mechanical stability and prolonging resistance to enzymatic degradation. Different classes of chemical cross-linkers have been developed, each characterized by specific advantages and limitations in terms of stability, calcification tendency, and biocompatibility.

Glutaraldehyde (GA) is among the earliest and most widely used chemical cross-linking agents for collagen-based biomaterials. It forms covalent bonds with amino groups present in collagen, resulting in a significant increase in structural stability. However, despite its effectiveness, glutaraldehyde-treated collagen has been associated with several drawbacks, including a marked tendency toward calcification and long-term instability. Degradation of glutaraldehyde-derived cross-linked structures may lead to the release of residual monomers, which are known to induce cytotoxic effects [29].

Epoxy compounds represent an alternative class of chemical cross-linkers developed to overcome some of the limitations associated with glutaraldehyde. These reagents are able to interact with multiple functional groups within the collagen structure, allowing for a more versatile cross-linking process. In vivo studies on subcutaneous implants in animal models have shown that epoxy-cross-linked grafts exhibit a lower tendency to calcify compared to glutaraldehyde-treated materials [30].

An alternative chemical cross-linker is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), often used in combination with N-hydroxysuccinimide (NHS). This method offers better biocompatibility than GA and effectively stabilizes collagen by promoting the formation of amide bonds between carboxyl and amine groups. EDC/NHS cross-linking is widely used in tissue engineering applications, particularly in scaffolds for bone and cartilage regeneration [31].

Another chemical approach is the acyl azide method, which promotes cross-link formation through activation of collagen carboxyl groups followed by reaction with neighboring amino groups. Although more complex from a processing standpoint, this method has been shown to produce highly stable collagen networks [32].

Physical Cross-Linking

Physical cross-linking methods are characterized by the absence of chemical cross-linking agents, which represents their main advantage in terms of biocompatibility, as no potentially harmful residual compounds are introduced into the collagen matrix. These approaches rely on physical stimuli to promote intermolecular interactions and structural stabilization.

The most applied physical processes to collagen include heating, drying, and irradiation. Among these, irradiation-based approaches typically involve exposure to short-wavelength ultraviolet (UV) light and are used to enhance the structural stability of collagen matrices. UV-induced cross-linking is a rapid physical method in which ultraviolet radiation promotes the formation of additional bonds between collagen molecules, thereby improving their resistance to degradation. This approach does not require chemical cross-linking agents and provides an effective sterilizing action. However, UV treatment alone generally results in a limited degree of cross-linking and may induce partial structural alterations in collagen. For this reason, UV irradiation is rarely employed as a standalone technique and is more commonly combined with light-activated substances to increase its effectiveness [33].

Another physical cross-linking method is dehydrothermal treatment (DHT), which involves exposing collagen to elevated temperatures under vacuum conditions. This process removes water molecules, promoting the formation of covalent bonds between amino groups. While DHT is a simple and non-toxic method, its cross-linking efficiency is lower than chemical methods, and it may not provide sufficient mechanical reinforcement for some applications [34].

1.8.2 Comparative Analysis of Cross-Linking Techniques

From a comparative standpoint, cross-linking techniques represent a necessary but inherently delicate compromise between structural stabilization and biological performance. Chemical cross-linking methods generally provide a higher degree of control over collagen resorption kinetics and mechanical reinforcement, making them particularly suitable for applications requiring prolonged barrier function or load-bearing capacity. However, their effectiveness is often accompanied by concerns related to cytotoxicity, altered tissue remodeling, and excessive stiffening when cross-link density is not carefully regulated. Such effects may negatively influence cell adhesion, proliferation, and overall tissue integration, ultimately limiting long-term regenerative outcomes.

In contrast, physical cross-linking approaches offer improved biocompatibility due to the absence of exogenous chemical agents and residual by-products. Nevertheless, their stabilizing effect is typically less pronounced and more difficult to fine-tune, which may result in insufficient resistance to enzymatic degradation in demanding clinical scenarios. Moreover, overly aggressive physical treatments can compromise collagen's native structure, reducing mechanical integrity rather than enhancing it.

Overall, no single cross-linking strategy can be considered universally optimal. The choice of method should therefore be guided by specific clinical requirements, balancing the need for extended resorption time with the preservation of collagen's biological functionality. In this context, the future of collagen-based biomaterials likely lies not in maximizing cross-link density, but in optimizing cross-linking strategies to achieve controlled degradation, adequate mechanical support, and favorable host–tissue interactions.

1.9 Clinical and Ethical Considerations

The clinical translation of regenerative medicine presents significant challenges that are closely intertwined with ethical considerations. From a clinical perspective, the safety and efficacy of regenerative treatments remain central concerns, as many stem cell interventions are still supported primarily by preclinical data or early-phase clinical trials. Potential risks include immune reactions, infection, inappropriate differentiation, and tumor or ectopic tissue formation, underscoring the necessity of rigorous preclinical testing, standardized manufacturing protocols, and long-term patient follow-up. The absence of universally accepted clinical guidelines and heterogeneous treatment protocols further complicates the comparison of outcomes and the establishment of evidence-based practices.

Ethically, the application of stem cell therapies must adhere to the core principles of autonomy, beneficence, non-maleficence, and justice. Informed consent is particularly critical in regenerative medicine, given the complexity of the underlying science and the experimental nature of many therapies. Patients must be provided with clear, accurate, and accessible information regarding potential benefits, risks, alternative treatments, and

the current level of scientific evidence. This is especially important when dealing with vulnerable populations or conditions for which conventional treatments offer limited options [35].

Equity and access represent additional ethical challenges, as stem cell therapies are often costly and not covered by insurance, potentially exacerbating existing healthcare disparities. The growing commercialization of regenerative medicine, coupled with the proliferation of clinics offering unproven or non-FDA-approved treatments, raises concerns about patient exploitation and the erosion of public trust. Clinicians and researchers must therefore maintain transparency regarding conflicts of interest and resist the premature promotion of therapies lacking robust clinical validation.

Ultimately, the responsible clinical implementation of stem cell therapies requires a balanced approach that promotes innovation while prioritizing patient safety and ethical integrity. Ongoing collaboration among clinicians, researchers, ethicists, regulatory authorities, and patients is essential to develop standardized protocols, ensure regulatory compliance, and foster the ethical advancement of regenerative medicine in clinical practice [36].

2 MATERIALS AND METHODS

2.1 Materials and Sample Preparation

All experimental activities and analyses described in this study were carried out at **Tiss'You S.r.l.**, a research and development company located in Domagnano (Republic of San Marino), specialized in the design and production of biomaterials and medical devices aimed at enhancing the natural regenerative capacity of the human body.

The collagen membrane employed in this study is **Collygen®**, a commercial medical device developed by Tiss'You S.r.l. for applications in Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR). Collygen® is composed of highly purified equine-derived type I atelocollagen, obtained through controlled processing steps aimed at removing antigenic telopeptides while preserving the native triple-helical structure of collagen. This composition ensures a high level of biocompatibility, safety, and complete resorbability, making the membrane suitable for clinical use in regenerative procedures.



Figure 2.1 Collygen® equine type I atelocollagen membrane used in this study for cross-linking and enzymatic degradation experiments.

In GBR applications, collagen membranes are traditionally used to act as passive barriers, preventing the infiltration of non-osteogenic soft tissues into the defect site. However, Collygen® is designed to play a more active role in the regenerative process, as the membrane compartment itself contributes to guiding tissue healing [37].

For the experimental activity described in this chapter, collagen membranes were manually cut into small specimens using sterile scissors. Each sample was weighed using an analytical balance, with individual masses ranging from approximately 2.5 to 3.5 mg. Samples were handled using sterile tweezers to minimize contamination.



Figure 2.2 Preparation of collagen membrane specimens prior to the cross-linking procedure. The Collygen® membrane was cut into standardized square samples, individually weighed using an analytical balance.

Based on preliminary handling and reproducibility considerations, standard reference conditions were defined to ensure consistency across experimental sets. A reference collagen mass of 2.8mg and a cross-linking solution volume of 100 μ L were selected as baseline conditions. When individual sample masses deviated from the reference value, reagent volumes were adjusted proportionally to maintain comparable reaction conditions.

Chemical cross-linking was performed using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) as a zero-length cross-linking agent. Fresh EDC stock solutions were prepared in ultrapure water or collagen buffer solution, depending on the experimental

condition, at concentrations ranging from 1 mM to 10 mM. Working solutions (0, 1, 2.5, 5 mM) were obtained by dilution of the stock solutions.




Figure 2.3 EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) reagent and freshly prepared aqueous solution used for collagen membrane cross-linking.

For each experimental set, collagen samples were divided into groups and immersed in 100 μ L of either ultrapure water (control) or EDC solutions at the selected concentrations.

Cross-linking reactions were carried out under continuous agitation at 500 rpm to ensure homogeneous exposure of the collagen membranes to the cross-linking solution throughout the reaction. The experimental design involved the systematic variation of selected reaction parameters to evaluate their effect on collagen stabilization. Specifically, cross-linking reaction was performed under different conditions of **temperature** (4°C, room temperature $\approx$ 20°C, and 40°C), **pH** of the reaction environment (pH 5 and pH 7), and **reaction time** (2 hours and 4 hours), depending on the experimental protocol.

Following cross-linking, all samples were freeze-dried overnight using a laboratory lyophilizer and stored under controlled conditions until further analysis.




Figure 2.4 Collagen membrane samples placed inside the freeze-dryer chamber prior to the lyophilization process.

2.2 Digestive Enzyme Analysis for Resorption Testing

Enzymatic digestion assays were performed to evaluate the resistance of native and cross-linked collagen membranes to degradation, simulating resorption phenomena relevant to Guided Bone Regeneration (GBR) applications. Digestion behavior was compared across samples obtained under different cross-linking conditions.

Prior to enzymatic digestion, all collagen samples underwent a controlled chemical and thermal denaturation step to expose cleavage sites and ensure reproducible enzymatic activity. A denaturing solution was freshly prepared by dissolving guanidine hydrochloride in 50 mM phosphate-buffered saline (PBS) adjusted to pH 8.0 using sodium hydroxide. Guanidine hydrochloride was used at a final concentration of 6 M,

while β -mercaptoethanol was added at a concentration of 2 mM to promote reduction of disulfide bonds and facilitate collagen unfolding.

Lyophilized collagen samples were incubated with 300 μ L of the denaturing solution and agitated at 60°C for 60 minutes. This step induced collagen denaturation while preserving the overall sample integrity. Following denaturation, samples were allowed to cool to room temperature.




Figure 2.5 Components of the denaturing solution used before enzymatic digestion: guanidine hydrochloride dissolved in 50 mM phosphate-buffered saline (PBS, pH 8.0) with the addition of β -mercaptoethanol.

To restore conditions compatible with enzymatic digestion, the denaturing medium was diluted by adding 600 μ L of a dilution buffer consisting of 50 mM PBS supplemented with 5 mM calcium chloride (CaCl_2). This dilution reduced the concentration of guanidine hydrochloride to below 2 M, a threshold compatible with proteolytic enzyme activity. Samples were gently agitated for 5 minutes to ensure homogeneous mixing.




Figure 2.6 Phosphate-buffered saline (PBS, 50 mM) and calcium chloride (CaCl_2) used for the preparation of the dilution buffer before Proteinase K digestion.

Enzymatic resorption testing was primarily conducted using **Proteinase K**, selected for its broad-spectrum proteolytic activity and effectiveness in degrading denatured collagen. Enzymatic digestion was performed under fixed experimental conditions, while comparing collagen samples previously subjected to different cross-linking protocols.

Proteinase K was added to each sample at a concentration proportional to the initial collagen mass, typically in the range of 50–100 $\mu\text{g/mL}$, corresponding to a standard enzyme dosage (1 $\times$). For selected experimental sets, increased enzyme concentrations were employed, corresponding to 1.5 $\times$ and 2 $\times$ the standard dosage, to investigate the effect of enzyme load on collagen degradation behavior. Apart from enzyme concentration, all digestion parameters were maintained constant throughout the assays.

Digestion reactions were carried out under continuous agitation, and the progression of collagen degradation was monitored over time. Digestion time was defined as the interval required for complete or near complete solubilization of the collagen sample and was recorded individually for each specimen as a quantitative indicator of enzymatic

resistance. Control samples consisting of non-cross-linked collagen membranes were included in each experimental set to establish baseline resorption behavior.

This enzymatic digestion protocol enabled systematic comparison of collagen resorption behavior as a function of cross-linking conditions, providing a controlled framework for assessing the effect of chemical cross-linking on collagen stability.

2.3 Analytical Techniques

Analytical evaluation of collagen degradation was primarily based on the assessment of enzymatic digestion kinetics, using digestion time as a quantitative indicator of collagen stability and resistance to resorption. Given the objective of comparing multiple cross-linking conditions rather than determining absolute degradation rates, a time-based analytical approach was selected as a robust and reproducible method.

For each experimental condition, collagen samples were visually and physically monitored throughout the digestion process. Complete digestion was operationally defined as the point at which the collagen sample was fully solubilized or reduced to non-cohesive fragments, with no visible solid structure remaining in the reaction medium. In cases where partial degradation occurred, digestion was considered ongoing until complete loss of structural integrity was observed.

Digestion times were recorded individually for each sample and systematically organized according to cross-linking concentration, incubation temperature, pH, and Proteinase K dosage. Multiple replicates were included for each condition to ensure consistency and reproducibility of the measurements. Control samples consisting of non-cross-linked collagen membranes were analyzed in parallel in every experimental set to establish baseline degradation behavior.

In selected experiments, samples were subjected to repeated washing steps using ultrapure water and centrifugation prior to freeze-drying, to remove residual reagents and digestion by-products. Lyophilized samples were visually inspected and weighed when applicable, providing additional qualitative support to the digestion time measurements.

Raw experimental data obtained from enzymatic digestion assays were systematically recorded and organized in spreadsheet files (Microsoft Excel). For each experimental condition, individual columns were used to report the relevant parameters, including EDC concentration (mM), sample mass (mg), volume of water/EDC solution (μL), Proteinase K dosage (1 $\times$, 1.5 $\times$, or 2 $\times$), and the corresponding digestion time (minutes). For conditions involving multiple replicates, mean digestion times were calculated directly within the spreadsheet to provide a representative value for each experimental group.

Subsequently, the organized datasets were processed directly within Microsoft Excel for data analysis and graphical representation. Graphs were generated by configuring standard chart parameters based on tabulated experimental data. Built-in spreadsheet functions were used to calculate mean digestion times for each experimental condition and to generate comparative plots using EDC concentration as the independent variable (x-axis) and digestion time as the dependent variable (y-axis). These plots enabled direct visualization of the relationship between cross-linking density and enzymatic resistance under different experimental conditions.

The use of spreadsheet-based data organization and analysis ensured consistency, traceability, and reproducibility of the analytical workflow. The resulting graphs were employed to support comparative evaluation of collagen resorption behavior as a function of cross-linking concentration and digestion parameters, without introducing assumptions related to absolute kinetic modeling, thereby maintaining focus on relative performance relevant to GBR applications.

3 RESULTS

3.1 Optimization of the Enzymatic Digestion Assay

Before evaluating the effect of EDC-mediated cross-linking on collagen enzymatic resistance, a series of preliminary experiments was performed to optimize the experimental conditions of the enzymatic digestion assay. Different combinations of incubation temperature and cross-linking time were progressively investigated at pH 7, together with different Proteinase K concentrations, to establish a reliable and reproducible protocol capable of differentiating collagen membranes treated with increasing EDC concentrations.

The initial optimization focused on the effect of incubation temperature while maintaining the remaining experimental parameters constant, namely pH 7, a cross-linking time of 2 h, and Proteinase K at the standard concentration. The digestion profiles obtained under these conditions are reported in Figures 3.1–3.3.




Figure 3.1 Mean enzymatic digestion times of collagen membranes treated with increasing EDC concentrations under the first experimental conditions (20°C, pH 7, 2 h cross-linking time, Proteinase K 1×). Error bars represent the standard deviation (SD).

The first optimization experiment was performed at **20°C**. Under these conditions, untreated collagen membranes reached complete digestion after an average of **14.0 ± 0.0 min**, while membranes treated with **1, 2.5, and 5 mM EDC** required **26.0 ± 4.4 min, 36.5**

± 3.5 min, and 55.0 ± 1.4 min, respectively. Complete enzymatic degradation was achieved for all experimental groups within the observation period, although digestion time progressively increased with increasing EDC concentration.




Figure 3.2 Mean enzymatic digestion times of collagen membranes treated with increasing EDC concentrations under the second experimental conditions (4°C, pH 7, 2 h cross-linking time, Proteinase K 1×). Error bars represent the standard deviation (SD).

To further investigate the influence of incubation temperature, the assay was repeated at 4°C while maintaining the remaining experimental parameters unchanged. Untreated collagen membranes reached complete digestion after an average of 14.0 ± 0.0 min, whereas average digestion times of 18.0 ± 0.0 min, 25.0 ± 2.0 min, and 87.0 ± 4.9 min were recorded for membranes treated with 1, 2.5, and 5 mM EDC, respectively. Compared with the previous experiment, the highest EDC concentration exhibited a marked increase in digestion time, although complete degradation was still observed for all samples.




Figure 3.3 Mean enzymatic digestion times of collagen membranes treated with increasing EDC concentrations under the third experimental conditions (40°C, pH 7, 2 h cross-linking time, Proteinase K 1×). Error bars represent the standard deviation (SD).

Based on the observations obtained from the first two experiments, a third assay was carried out at **40°C**. Under these conditions, untreated collagen membranes reached complete digestion after an average of **16.0 ± 0.7 min**, whereas membranes treated with **1 mM** and **2.5 mM** EDC required **24.0 ± 0.0 min** and **52.0 ± 1.4 min**, respectively, to achieve complete degradation. In contrast, collagen membranes treated with **5 mM** EDC did not reach complete digestion within the experimental observation period, indicating a markedly higher resistance to Proteinase K digestion than that observed under the previous experimental conditions.

The results obtained from the temperature optimization indicated that **40°C** provided the most appropriate experimental conditions for the enzymatic digestion assay, allowing clear differentiation among collagen membranes treated with increasing EDC concentrations. Following the selection of the incubation temperature, additional optimization experiments were performed by evaluating different combinations of reaction pH, cross-linking time, and Proteinase K concentration. These investigations led to the definition of the final experimental protocol, consisting of collagen cross-linking performed at **40°C** and **pH 7** for **2 h**, followed by enzymatic digestion using **Proteinase K at the standard concentration (1×)**. The optimized protocol was subsequently employed for all experiments presented in the following sections.

3.2 Evaluation of EDC-Mediated Cross-Linking on Enzymatic Resistance

Following the optimization of the experimental conditions, the enzymatic digestion assay was used to evaluate the influence of EDC concentration on the resistance of collagen membranes to Proteinase K degradation. The final digestion times obtained using the optimized protocol are summarized in Table 3.1.

EDC concentration (mM)	Mean digestion time $\pm$ SD (min)
0	16.0 $\pm$ 0.7
1	24.0 $\pm$ 0.0
2.5	52.0 $\pm$ 1.4
5	ND

Table 3.1 Mean enzymatic digestion times of collagen membranes treated with increasing EDC concentrations under the optimized experimental conditions (40°C, pH 7, 2 h cross-linking time, Proteinase K 1×). Data are reported as mean $\pm$ standard deviation (SD).

Untreated collagen membranes (0 mM EDC) exhibited the shortest digestion time, reaching complete degradation after an average of **16.0 $\pm$ 0.7 min**. The introduction of EDC as a cross-linking agent progressively increased the resistance of collagen membranes to enzymatic digestion.

Membranes treated with **1 mM EDC** required **24.0 $\pm$ 0.0 min** to reach complete degradation, corresponding to an increase of approximately **55%** compared with untreated collagen membranes. Increasing the EDC concentration to **2.5 mM** produced a further prolongation of the digestion process, with complete degradation occurring after an average of **52.0 $\pm$ 1.4 min**, corresponding to more than three times the digestion time observed for the control group.

The most evident effect was observed for collagen membranes treated with **5 mM EDC**. Under the optimized experimental conditions, these samples did not undergo complete enzymatic degradation within the experimental observation period and were therefore

classified as **Not Digested (ND)**. This behavior clearly distinguished the highest EDC concentration from all the other experimental groups.

Overall, the obtained results demonstrated a progressive increase in collagen resistance to enzymatic degradation as the EDC concentration increased. The gradual prolongation of digestion time observed across the investigated concentrations indicates that EDC-mediated cross-linking effectively stabilized the collagen matrix, reducing its susceptibility to Proteinase K degradation under the selected experimental conditions. The linear regression lines reported in Figures 3.1-3.3 further support this concentration-depend trend, as indicated by the high coefficients of determination (R^2).

4 DISCUSSION

4.1 Interpretation of Results

The results obtained in the present study demonstrated that EDC concentration had a direct influence on the enzymatic resistance of collagen membranes. Under the optimized experimental conditions, progressively longer digestion times were observed as the concentration of the cross-linking agent increased, indicating that EDC effectively modulated the degradation behavior of the collagen matrix.

The gradual increase in digestion time suggests that increasing the degree of cross-linking enhanced the structural stability of the collagen membranes. While untreated samples were rapidly degraded by Proteinase K, cross-linked membranes exhibited progressively greater resistance to enzymatic digestion. This trend became particularly evident at the highest EDC concentration (5 mM), where complete degradation was not achieved within the experimental observation period.

From a practical perspective, these findings indicate that the enzymatic digestion assay was able to discriminate between collagen membranes characterized by different degrees of stabilization. The optimized protocol therefore proved to be a simple and reproducible *in vitro* method for evaluating the influence of EDC concentration on collagen degradation behavior.

The observed concentration-dependent behavior is particularly relevant for the development of collagen membranes intended for guided bone regeneration. An ideal barrier membrane should maintain its structural integrity for a sufficient period to support the regenerative process while remaining biodegradable after tissue healing. The possibility of modulating membrane stability by adjusting the concentration of the cross-linking agent may therefore represent an important strategy for tailoring the degradation profile according to specific clinical requirements.

Although the present work was limited to an *in vitro* enzymatic degradation model, the obtained results provide useful information for the optimization of collagen-based biomaterials. The optimized assay represents a practical experimental approach for

comparing different cross-linking conditions and may serve as a useful preliminary screening method before more advanced biological and mechanical evaluations.

4.2 Effectiveness of Cross-Linking Methods

The results obtained in the present study confirm that EDC-mediated cross-linking represents an effective strategy for controlling the enzymatic degradation behavior of collagen membranes. By increasing the concentration of the cross-linking agent, a progressive enhancement of membrane stability was observed, demonstrating that the degradation profile can be modulated according to the selected treatment conditions.

Among the various cross-linking approaches described for collagen-based biomaterials, EDC has been widely employed because it improves membrane stability while preserving the intrinsic characteristics of collagen. Unlike other chemical cross-linking agents, EDC does not become permanently incorporated into the collagen structure, making it particularly suitable for biomedical applications where biocompatibility is an essential requirement.

The results obtained in this work are consistent with these characteristics. The gradual increase in enzymatic resistance observed with increasing EDC concentration suggests that the cross-linking treatment effectively reinforced the collagen network without completely preventing biodegradation. Instead, the degradation process was progressively delayed, allowing the stability of the membrane to be adjusted according to the applied EDC concentration.

From an application perspective, this behaviour is particularly relevant for guided bone regeneration. Barrier membranes should maintain their structural integrity during the early stages of tissue healing while gradually degrading once their function has been fulfilled. The possibility of regulating the degradation rate through EDC-mediated cross-linking may therefore contribute to the development of collagen membranes with properties tailored to different clinical requirements.

Overall, the findings of the present study support the use of EDC as an effective cross-linking agent for collagen-based GBR membranes. The optimized enzymatic digestion assay proved to be a useful approach for evaluating the stabilizing effect of different EDC concentrations and may represent a practical tool for the preliminary assessment of future collagen-based biomaterials.

4.3 Future Directions for Collagen-Based GBR Biomaterials

Although the present study demonstrated that EDC-mediated cross-linking effectively modulates the enzymatic degradation behaviour of collagen membranes, further investigations are required to fully assess their potential for guided bone regeneration applications.

The enzymatic digestion assay developed in this work provides a simple and reproducible in vitro method for evaluating collagen stability under controlled conditions. However, enzymatic degradation represents only one aspect of membrane performance. Future studies should integrate these findings with additional mechanical, biological, and physicochemical evaluations in order to obtain a more comprehensive characterization of the biomaterial.

Mechanical characterization, including tensile strength and elasticity measurements, would provide valuable information on the ability of cross-linked membranes to maintain structural integrity during the healing process. Similarly, biological investigations involving cell viability, proliferation, and adhesion assays would allow the assessment of the biocompatibility of collagen membranes treated with different EDC concentrations.

Another important step would be the validation of the present findings through in vivo studies. Since the physiological environment is considerably more complex than an in vitro enzymatic digestion model, animal studies would be necessary to evaluate membrane degradation under biological conditions and to determine whether the observed degradation profiles accurately reflect the behaviour of collagen membranes during bone regeneration.

The optimization of EDC concentration also deserves further investigation. While increasing EDC concentration improved enzymatic resistance, excessively stable membranes may remain in the implantation site longer than required, potentially interfering with the normal tissue remodeling process. Future research should therefore focus on identifying the optimal balance between membrane stability and biodegradability according to the intended clinical application.

Overall, the experimental approach presented in this study may represent a useful platform for the preliminary evaluation of novel collagen-based biomaterials. The combination of enzymatic degradation assays with complementary biological and mechanical analyses could contribute to the development of next-generation GBR membranes characterized by improved performance and more predictable clinical outcomes.

5 CONCLUSIONS

The present study investigated the effect of EDC-mediated cross-linking on the enzymatic degradation behavior of collagen membranes intended for guided bone regeneration (GBR) applications. A reproducible *in vitro* enzymatic digestion assay based on Proteinase K was successfully developed and optimized to evaluate the influence of different EDC concentrations on collagen stability.

The optimization of the experimental protocol demonstrated the importance of selecting appropriate assay conditions in order to obtain clear discrimination among collagen membranes subjected to different cross-linking treatments. The final protocol, consisting of cross-linking performed at 40°C and pH 7 for 2 h followed by enzymatic digestion using Proteinase K at the standard concentration, proved to be suitable for evaluating differences in collagen membrane degradation behavior.

The experimental results showed a clear concentration-dependent relationship between EDC treatment and enzymatic resistance. Increasing the concentration of the cross-linking agent progressively prolonged the digestion time of collagen membranes, while the highest EDC concentration prevented complete degradation within the experimental observation period. These findings indicate that EDC-mediated cross-linking effectively modulates collagen stability, allowing the degradation behavior of collagen membranes to be tailored through the selected EDC concentration.

From a biomedical perspective, the ability to regulate membrane degradation is particularly important for guided bone regeneration, where barrier membranes are required to maintain their structural integrity during the initial stages of healing before being gradually resorbed. The results obtained in this study suggest that modulation of EDC concentration may represent a useful strategy for tailoring collagen membrane stability according to specific regenerative requirements.

Although the present work was limited to an *in vitro* enzymatic degradation model, the optimized experimental approach provides a practical method for the preliminary evaluation of collagen-based biomaterials. Future investigations integrating mechanical

characterization, biological assessment, and in vivo studies will further contribute to the development of collagen membranes with improved performance for regenerative medicine applications.

Overall, the findings of this study demonstrate that EDC-mediated cross-linking is an effective approach for enhancing the enzymatic stability of collagen membranes and that the optimized digestion assay represents a reliable tool for investigating the relationship between cross-linking conditions and collagen degradation behavior. These results provide a useful foundation for the future design and optimization of collagen-based GBR biomaterials.

6 BIBLIOGRAPHY

- [1] M. M. Stevens, "Biomaterials for bone tissue engineering," *Materials Today*, vol. 11, pp. 18-25, 2008.
- [2] A. Terzic, M. A. Pfenning, G. J. Gores and C. J. Harper, "Regenerative Medicine Build-Out," *Stem Cells Translational Medicine*, vol. 4, no. 12, 2015.
- [3] H. L. Greenwood, H. Thorsteinsdottir, G. Perry, J. Renihan, P. Singer and A. Daar, "Regenerative medicine: New opportunities for developing countries," *International Journal of Biotechnology*, vol. 8, no. 1/2, pp. 60-77, 2006.
- [4] A. S. Slingerland, A. I. P. M. Smits and C. V. C. Bouten, "Then and now: hypes and hopes of regenerative medicine," *Trends in Biotechnology*, vol. 31, no. 3, pp. 121-3, 2013.
- [5] G. Kolios and Y. Moodley, "Introduction to Stem Cells and Regenerative Medicine," *Respiration*, vol. 85, no. 1, pp. 3-10, 2012.
- [6] F. J. Santa Cruz-Pavlovich, A. J. Bolaños-Chang, X. I. Del Rio-Murillo, G. A. Aranda-Preciado, E. M. Razura-Ruiz, A. Santos and J. Navarro-Partida, "Beyond Vision: An Overview of Regenerative Medicine and Its Current Applications in Ophthalmological Care," *Cells*, vol. 13, no. 2, p. 179, 2024.
- [7] J. P. Vacanti and R. Langer, "Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation," *The Lancet*, vol. 354, 1999.
- [8] A. Mazzoli, "Tissue Engineering Conventional Techniques (Biomaterials for medical devices and prostheses course)," 2023.
- [9] T. Nii and Y. Katayama, "Biomaterial-Assisted Regenerative Medicine," *International Journal of Molecular Sciences*, vol. 22, no. 16, 2021.
- [10] L.-Y. Zhang, Q. Bi, C. Zhao, J.-Y. Chen, M.-H. Cai and X.-Y. Chen, "Recent Advances in Biomaterials for the Treatment of Bone Defects," *Organogenesis*, vol. 16, no. 4, 202.

- [11] W. Wei, Y. Ma, X. Yao, W. Zhou, X. Wang, C. Li, J. Lin, Q. He, S. Leptihn and H. Ouyang, "Advanced hydrogels for the repair of cartilage defects and regeneration," *Bioactive materials*, vol. 6, no. 4, pp. 998-1011, 2021.
- [12] K. E. Tansey, J. L. Seifert, B. Botterman, M. R. Delgado and M. I. Romero, "Peripheral nerve repair through multi-luminal biosynthetic implants," *Annals of Biomedical Engineering*, vol. 39, no. 6, pp. 1815-28, 2011.
- [13] H. Lin, G. Yang, J. Tan and R. S. Tuan, "Influence of decellularized matrix derived from human mesenchymal stem cells on their proliferation, migration and multi-lineage differentiation potential," *Biomaterials*, vol. 33, no. 18, pp. 4480-9, 2012.
- [14] J.-L. Zou, S. Liu, J.-H. Sun, W.-H. Yang, W.-H. Xu, Z.-L. Rao, B. Jiang, Q.-T. Zhu, X.-L. Liu, J.-L. Wu, C. Chang, H.-Q. Mao, E.-A. Ling, D.-P. Quan and Y.-S. Zeng, "Peripheral Nerve-Derived Matrix Hydrogel Promotes Remyelination and Inhibits Synapse Formation," *Advanced Functional Materials*, vol. 28, no. 13, 2018.
- [15] S. P. Bruder and A. I. Caplan, "Bone regeneration through cellular engineering," in *Principles of Tissue Engineering*, pp. 683-696.
- [16] M. G. Patino, M. E. Neiders, S. Andreana, B. Noble and R. E. Cohen, "Collagen: an overview," *Implant Dentistry*, no. 11, pp. 280-5, 2002.
- [17] K. Gelse, E. Pöschl and T. Aigner, "Collagens - structure, function, and biosynthesis," *Advanced Drug Delivery Reviews*, 2003.
- [18] A. M. Ferreira, P. Gentile, V. Chiono and G. Ciardelli, "Collagen for bone tissue regeneration," *Acta Biomaterialia*, 2012.
- [19] M. G. Patino, M. E. Neiders, S. Andreana, B. Noble and R. E. Cohen, "Collagen: An Overview," *Implant Dentistry*, no. 11(3), pp. 280-5, 2002.
- [20] V. Kolliopoulos and B. A. Harley, "Mineralized collagen scaffolds for regenerative engineering applications," *Current Opinion in Biotechnology*, 2004.
- [21] M. Toledano, S. Asady, M. Toledano-Ososrio, F. Garcia-Godoy, M. A. Serrera-Figallo, J. A. Benítez.-García and R. Osorio, "Differential Biodegradation Kinetics of Collagen Membranes for Bone Regeneration," *Polymers*, 2020.
- [22] M. C. Bottino, V. Thomas, G. Schmidt, Y. K. Vohra, T. M. Chu, M. J. Kowolik and G. M. Janowski, "Recent Advances in the Development of GTR/GBR Membranes

- for Periodontal Regeneration--a Materials Perspective," *Dental Materials*, no. 28, pp. 703-721, 2012.
- [23] C. Vallecillo, M. Toledano-Osorio, M. Vallecillo-Rivas, M. Toledano and R. Osorio, "In Vitro Biodegradation Pattern of Collagen Matrices for Soft Tissue Augmentation.," *Polymers*, no. 13, p. 2633, 2021.
- [24] C. Vallecillo, M. T. Osorio, N. Infante, M. J. Ávalos, M. Vallecillo-Rivas, C. D. Lynch and M. Toledano, "In Vitro Degradation of Collagen-Based Membranes for Guided Bone Regeneration After Zn-Ions or Doxycycline Functionalization," *Polymers*, 2024.
- [25] A. Kang and J. Gross, "Relationship between the intra and intermolecular cross-links of collagen.," *Proceedings of the National Academy of Sciences*, vol. 67, no. 3, pp. 1307-1314, 1970.
- [26] M. J. Buehler, "Nanomechanics of collagen fibrils under varying cross-link densities: atomistic and continuum studies.," *Journal of Mechanical Behavior of Biomedical Materials*, vol. 1, pp. 59-67, 2008.
- [27] M. Mohammadkhah and S. Klinge, "Review paper: The importance of consideration of collagen cross-links in computational models of collagen-based tissues," *Journal of the Mechanical Behavior of Biomedical Materials*, vol. 148, 2023.
- [28] M. G. Dunn, P. N. Avasarala and J. P. Zawadsky, "Optimization of extruded collagen fibers for ACL reconstruction," *Journal of Biomedical Materials Research*, vol. 27, pp. 1545-1552, 1993.
- [29] L. L. Huang-Lee, D. T. Cheung and M. E. Nimni, "Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived crosslinks," *Journal of Biomedical Materials Research*, vol. 24, pp. 1185-1201, 1990.
- [30] E. Imamura, O. Sawatani, H. Koyanagi, Y. Noishiki and T. Miyata, "Epoxy compounds as a new cross-linking agent for porcine aortic leaflets: subcutaneous implant studies in rats," *Journal of Cardiac Surgery*, vol. 4, pp. 50-57, 1989.

- [31] E. Khor, "Methods for the treatment of collagenous tissues for bioprotheses," *Biomaterials*, vol. 18, pp. 95-105, 1997.
- [32] K. Anselme, H. Petite and D. Herbage, "Inhibition of calcification in vivo by acyl azide cross-linking of a collagen-glycosaminoglycan sponge," *Matrix*, vol. 12, pp. 264-273, 1992.
- [33] K. Adamiak and A. Sionkowska, "Current methods of collagen cross-linking: Review," *International Journal of Biological Macromolecules*, vol. 161, pp. 550-560, 2020.
- [34] J. K. Law, J. R. Parsons, F. H. Silver and A. B. Weiss, "An evaluation of purified reconstituted type 1 collagen fibers," *Journal of Biomedical Materials Research*, vol. 23, pp. 961-977, 1989.
- [35] P. Jayaram, R. M. Danilkowicz and X. Yuan, "Ethical and Regulatory Considerations Related to Regenerative Medicine," *HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery*, 2025.
- [36] E. Lee, "The Ethical Landscape of Regenerative Medicine," *Stem Cell Research and Regenerative Medicine*, vol. 7, 2024.
- [37] Tiss'you s.r.l., [Online]. Available: www.tissyou.com/products/collygen/.